{"created":"2023-05-15T16:39:36.546303+00:00","id":13565,"links":{},"metadata":{"_buckets":{"deposit":"8bfd77a9-8a11-46cc-88ee-ca38283a792c"},"_deposit":{"created_by":2,"id":"13565","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"13565"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00013565","sets":["8:9"]},"author_link":["48980","48985","48981","48979","48984","48983","48982"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"10","bibliographicPageEnd":"3100","bibliographicPageStart":"3086","bibliographicVolumeNumber":"56","bibliographic_titles":[{"bibliographic_title":"Digestive Diseases and Sciences"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"BACKGROUND: α-fetoprotein (AFP) is used as a marker for hepatocellular carcinoma (HCC), which is influenced by hepatitis. Protein-induced vitamin K absence or antagonist II (PIVKA-II) is a sensitive diagnostic marker. Changes in these markers after treatment may reflect curability and predict outcome. METHODS: We conducted an analysis of prognosis in 470 HCC patients who received curative treatments, and examined the relationship between changes in AFP and PIVKA-II levels after 1 month of treatment in 156 patients. Subjects were divided into three groups according to changes in both levels: (1) normal (L) group before treatment, (2) normalization (N) or (3) decreased but still above normal level or unchanged (ANU) group after treatment. RESULTS: High AFP and PIVKA-II levels were significantly associated with poor tumor-free and overall survival. The presence of large size and advanced stage were significantly associated with prevalence of DU group. Overall survival in the AFP-L group was significantly better than that of other groups and overall survival in PIVKA-II-L and N groups were significantly better than that of the PIVKA-II-ANU groups. The combination of changes in the AFP- ANU and PIVKA-II- ANU groups showed the worst tumor-free and overall survivals. Multivariate analysis identified high pre-treatment levels of AFP and PIVKA-II and combination of AFP- ANU and PIVKA-II- ANU as significant determinants of poor tumor-free and overall survival, particularly in patients who underwent hepatectomy. CONCLUSION: We conclude that high levels of AFP or PIVKA-II after treatment for HCC did not sufficiently reflect curative efficacy of treatment and reflected a poor predictor of prognosis in HCC patients.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Digestive Diseases and Sciences, 56(10), pp.3086-3100; 2011","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer"}]},"item_2_relation_11":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"21706206","subitem_relation_type_select":"PMID"}}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1007/s10620-011-1796-6","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© Springer Science+Business Media, LLC 2011"},{"subitem_rights":"The original publication is available at www.springerlink.com"}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA00161107","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"01632116","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"15732568","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Nanashima, Atsushi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Taura, Naota"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Abo, Takafumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ichikawa, Tatsuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sakamoto, Ichiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nagayasu, Takeshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakao, Kazuhiko"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-22"}],"displaytype":"detail","filename":"DDS56_3086.pdf","filesize":[{"value":"267.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"DDS56_3086.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/13565/files/DDS56_3086.pdf"},"version_id":"9f6afb01-fc8a-4645-8f79-319e9154da85"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"AFP","subitem_subject_scheme":"Other"},{"subitem_subject":"Hepatocellular carcinoma","subitem_subject_scheme":"Other"},{"subitem_subject":"PIVKA-II","subitem_subject_scheme":"Other"},{"subitem_subject":"Post-curative treatment change","subitem_subject_scheme":"Other"},{"subitem_subject":"Survival","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Tumor Marker Levels Before and After Curative Treatment of Hepatocellular Carcinoma as Predictors of Patient Survival.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Tumor Marker Levels Before and After Curative Treatment of Hepatocellular Carcinoma as Predictors of Patient Survival."}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2011-09-01"},"publish_date":"2011-09-01","publish_status":"0","recid":"13565","relation_version_is_last":true,"title":["Tumor Marker Levels Before and After Curative Treatment of Hepatocellular Carcinoma as Predictors of Patient Survival."],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T00:35:54.168145+00:00"}